证券代码：600332 证券简称：白云山 公告编号：2024－022 广州白云山医药集团股份有限公司 关于分公司收到化学原料药上市申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（以下简称"本公司"）分公司 广州白云山医药集团股份有限公司白云山化学制药厂（以下简称"白云 山化学制药厂"）于2024年4月16日收到国家药品监督管理局核准签发的 枸橼酸西地那非化学原料药上市申请批准通知书。现将相关情况公告如 下： 一、药物的基本情况 化学原料药名称：枸橼酸西地那非 包装规格：5Kg/桶、10Kg/桶、20Kg/桶、25Kg/桶 通知书编号：2024YS00309 通知书有效期：至2029年4月15日 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审 查，本品符合药品注册的有关规定要求，批准本品生产。 1 二、药物的其它相关情况 枸橼酸西地那非主要适用于治疗性勃起功能障碍。白云山化学制药 厂于2014年获得枸橼酸西地那非原料药的生产批 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 ( 於中華人民共和國註冊成立之股份有限公司 ) （H 股股份代碼：0874） 董事會會議召開日期 中國廣州，2024 年 4 月 12 日 於本公告日，本公司董事會成員包括執行董事李楚源先生、楊軍先生、程寧女士、劉菊妍女士、張 春波先生、吳長海先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶 清女士。 1 廣州白雲山醫藥集團股份有限公司（「本公司」）董事會（「董事會」）茲通 告謹定於 2024 年 4 月 26 日（星期五）舉行董事會會議，藉以審議及批准 本公司及其附屬公司截至 2024 年 3 月 31 日止三個月未經審計財務業績及 處理其他事項（如有）。 廣州白雲山醫藥集團股份有限公司 董事會 ...

证券代码：600332 证券简称：白云山 广州白云山医药集团股份有限公司 投资者关系活动记录表 R特定对象调研 R分析师会议 £媒体采访 £业绩说明会 投资者关系活 动类别 □新闻发布会 R路演活动 □现场参观 £其他 召开方式 现场路演、线上调研 时间 2024年3月1日至2024年3月31日 地点 上海、北京及香港三地路演场地会议室，公司会议室 副董事长程宁女士、执行董事张春波先生、执行董事兼总经 理黎洪先生、副总经理郑坚雄先生、董事会秘书黄雪贞女 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 呈交日期: 2024年4月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 00874 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 219,900,000 | RMB | | 1 RMB | | 219,900,000 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 219,900,000 | RMB | | 1 RMB | | 219,900,000 | | 2. 股份分類 | 普通股 | 股份類別 | A | | ...

证券研究报告 | 公司动态点评 2024 年 03月 29日 白云山（600332.SH） 23 年业绩稳健增长，24 年高质量发展可期 财务指标 2022A 2023A 2024E 2025E 2026E 增持（维持评级） 营业收入（百万元） 70,788 75,515 81,013 86,289 91,125 股票信息 增长率yoy（%） 2.6 6.7 7.3 6.5 5.6 归母净利润（百万元） 3,967 4,056 4,545 5,079 5,665 行业 医药 增长率yoy（%） 6.6 2.2 12.1 11.8 11.5 2024年3月28日收盘价（元） 28.65 ROE（%） 12.6 11.6 12.0 12.1 12.2 总市值（百万元） 46,578.91 EPS最新摊薄（元） 2.44 2.49 2.80 3.12 3.48 流通市值（百万元） 40,278.78 P/E（倍） 11.7 11.5 10.2 9.2 8.2 总股本（百万股） 1,625.79 P/B（倍） 1.5 1.3 1.2 1.1 1.0 流通股本（百万股） 1,405.89 资料来源：公司财报，长城证券产 ...

上述企业通过高新技术企业认定后，根据国家相关规定，自获得 高新技术企业认定后连续三年内（2023年、2024年和2025年）可享受 国家关于高新技术企业的相关优惠政策，即按15%的税率缴纳企业所 得税，上述税收优惠政策不影响本公司已披露的2023年度财务数据。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 及子公司广州白云山中一药业有限公司、广州白云山星群（药业）股 份有限公司等13家企业已通过高新技术企业认定，并收到由广东省科 学技术厅、广东省财政厅、国家税务总局广东省税务局联合颁发的《高 新技术企业证书》，详细情况见下表： | 序号 | 企业名称 | 证书编号 | | | 发证日期 | | | | 有效 | 备注 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | | 期 | | | 1 | 本公司 | GR202344004122 | 2023 | 年 | 12 | 月 | 28 | 日 | 三年 | 重新认定 | | 2 | 广州白云山中一药业有限公司 | GR20 ...

Financial Performance - The company achieved a consolidated net profit attributable to shareholders of RMB 4,055,678,691.49 for the year 2023, with the parent company reporting a net profit of RMB 1,684,022,544.74[4]. - The company's revenue for 2023 reached RMB 75,515,404 thousand, an increase of 6.68% compared to RMB 70,788,155 thousand in 2022[19]. - Net profit attributable to shareholders for 2023 was RMB 4,055,679 thousand, reflecting a growth of 2.25% from RMB 3,966,522 thousand in the previous year[19]. - The net profit after deducting non-recurring gains and losses increased by 9.53% to RMB 3,635,521 thousand from RMB 3,319,308 thousand in 2022[19]. - The company reported a total profit of RMB 5,110,498 thousand for 2023, which is a 1.33% increase year-on-year[28]. - The company's total liabilities increased by 2.15% to RMB 41,909,054 thousand from RMB 41,027,441 thousand in 2022[19]. - The return on equity for 2023 was 11.61%, a decrease of 0.76 percentage points from 12.37% in 2022[21]. - Basic earnings per share for 2023 were RMB 2.495, up from RMB 2.440 in 2022, representing a growth of 2.25%[21]. - The asset-liability ratio improved to 53.33% in 2023, down from 54.95% in 2022, indicating better financial stability[21]. - The company achieved a total revenue of RMB 75,515,404 thousand in 2023, representing a year-on-year growth of 6.68%[49]. Dividends and Profit Retention - A cash dividend of RMB 0.749 per share (including tax) is proposed, totaling RMB 1,217,717,420.80, based on a total share capital of 1,625,790,949 shares as of the end of 2023[5]. - The company plans to retain the remaining undistributed profits for future allocation, with no capital reserve fund conversion into share capital for this year[5]. - The company has a retained undistributed profit of RMB 8,389,265,344.67 at the end of the reporting period after accounting for the cash dividend and statutory surplus reserve[4]. Risk Management and Compliance - The report indicates that there are no significant risks that materially affect the company's production and operations during the reporting period[5]. - The company has confirmed that there are no non-operating fund occupations by controlling shareholders and their related parties[5]. - The financial report has been audited by Da Xin Accounting Firm, which issued a standard unqualified audit report[4]. - The board of directors and senior management have confirmed the accuracy and completeness of the financial report[4]. - The company has implemented a comprehensive risk management system to identify, assess, and manage significant risks, ensuring effective internal controls and regular reporting to the board[136]. - The internal control and risk management systems have been evaluated as sufficient and effective by the audit committee, confirming compliance with corporate governance codes[135]. Research and Development - The company invested RMB 782 million in R&D expenses for the year 2023[32]. - The company has established 3 provincial-level and 1 municipal-level research platforms[32]. - The company has 5 national-level R&D institutions and 17 provincial-level technology centers, enhancing its technological innovation capabilities[53]. - The company has a total of 154 ongoing research projects, focusing on new drug development and consistency evaluation of generic drugs[96]. - The major R&D project for rabies vaccine development saw an investment of RMB 68,290.30 thousand, reflecting a significant increase in R&D efforts[105]. Market Expansion and Product Development - The company launched new health products, including various flavored herbal teas and fruit juice beverages, to expand its product offerings[30]. - The company expanded its retail network, increasing the number of retail outlets to 157, with 51 designated for dual-channel operations[29]. - The company is actively pursuing internationalization by participating in international exhibitions and accelerating local adaptations of its products[30]. - The company is investing in new healthcare projects, including hospitals and healthcare service companies, to enhance its market presence[46]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product portfolio[159]. Corporate Governance - The company has a governance structure that guarantees equal rights for all shareholders, especially minority shareholders[145]. - The company has established a written service contract for each director and supervisor, with a term of approximately three years[185]. - The company maintains liability insurance for directors, supervisors, and senior executives to provide protection against legal actions[186]. - The board is responsible for formulating and reviewing corporate governance policies and compliance with legal regulations[195]. - The company has appointed independent non-executive directors with extensive experience in various medical and financial fields, enhancing governance and oversight[161][162][163][164]. Financial Management and Compensation - The total compensation for the chairman, Li Chuyuan, was RMB 1,743.68 thousand for the reporting period[173]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period was RMB 20,824.85 thousand[181]. - The remuneration decision process for directors and senior management involves the board's remuneration and assessment committee, which proposes remuneration based on industry standards and company performance[179]. - The company’s independent directors' remuneration is determined based on proposals approved by the shareholders' meeting[181]. Operational Efficiency and Cost Management - The company aims to enhance management efficiency and reduce production costs through optimization strategies[34]. - The company has established a unified procurement platform to enhance cost efficiency and risk management in sourcing raw materials[41]. - The cost of raw materials accounted for 74.20% of total costs, with a slight decrease in the proportion compared to 75.85% in the previous year[63]. - The company is focused on advancing its research and development capabilities, including new drug development and collaboration with hospitals and research institutions[121].

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.gybys.com.cn, the company's third-party website at www.hmdatalink.com/C14070/tc/announcement.php and the HKEXnews website at www.hkexnews.hk in place of printed copies. You need to proactively check the Company's website and the HKEXnews website to keep up with the publication of Corporate Communications. You should liaise with your bank(s), brok ...

(A joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立之股份有限公司） （H share Stock Code H 股股份代碼：0874） Dear registered shareholder(s), Arrangement of Electronic Dissemination of Corporate Communications Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effec ...

化学原料药注册标准编号：YBY61512024 证券代码：600332 证券简称：白云山 公告编号：2024－018 广州白云山医药集团股份有限公司 关于分公司收到化学原料药上市申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（以下简称"本公司"）分公司 广州白云山医药集团股份有限公司白云山化学制药厂（以下简称"白云 山化学制药厂"）于2024年3月20日收到国家药品监督管理局核准签发的 头孢克肟化学原料药上市申请批准通知书。现将相关情况公告如下： 一、药物的基本情况 化学原料药名称：头孢克肟 包装规格：25千克/桶 通知书编号：2024YS00226 受理号：CYHS2260303 白云山化学制药厂于2003年获得头孢克肟化学原料药的新药证书及 生产批文（国药准字H20030043，登记号Y20190005402）。本品为白云山 化学制药厂采用新的生产工艺制备的头孢克肟，完成相关研究、提升质 量标准后在2022年6月按照不同登记号向国家食品药品监督管理局进行 登记获得受理。 ...